Japan Insulin Infusion Pump Market

Japan Insulin Infusion Pump Market Analysis

The Japan Insulin Infusion Pump Market size in terms of Greater Than-4.10 is expected to grow from USD 58.25 million in 2025 to USD 71.22 million by 2030, at a CAGR of greater than 4.1% during the forecast period (2025-2030).

The Japanese market for diabetes insulin infusion pumps is witnessing a robust growth trajectory, fueled by the increase in diabetes cases and proactive industry initiatives, including expanding product portfolios and the increasing prevalence of diabetes.

With Japan's diabetic population on the rise, the demand for insulin infusion pumps that are crucial for managing blood glucose levels is poised for a significant uptick. Data from the IDF Diabetes Atlas highlighted the widespread prevalence of diabetes across various age brackets, with a pronounced concentration among the working-age segment. In 2022, Japan reported 5.5 thousand diabetics under 20, 43.3 thousand aged 20-59, and 30.5 thousand above 60. Such a high concentration of diabetic people in the working-age group affects the nation's healthcare expenditure. According to IDF Diabetes Atlas, Japan's diabetes cases are expected to rise further.

As the diabetic populace expands, Japan is experiencing a surge in new product introductions and guideline updates. For instance, in February 2023, Medtronic Japan Co. Ltd secured manufacturing and sales approval for the MiniMed 780G System. This marked a milestone as Japan's first insulin pump featuring the Advanced Hybrid Closed Loop technology with automatic insulin injection for basal and correction insulin.

The growing prevalence of diabetes in Japan is driving significant market growth. Market players are responding with innovative products and expanded capacities, positioning the market for continued expansion.

Japan Insulin Infusion Pump Market Trends

The Insulin Pump Segment is Expected to Witness Growth Over the Forecast Period

The insulin pump mirrors the human pancreas; it administers insulin continuously or as needed, replacing traditional daily injections or insulin pens. Widely adopted by individuals with type 1 diabetes (T1DM), these pumps offer a time-tested alternative, ensuring near-physiological insulin delivery when the pancreas falters. Notably, pumps equipped with remote controls empower parents to manage insulin dosages from a distance, even as their child plays or eats.

Compared to injections, insulin pumps offer more precise dosing, minimize blood glucose fluctuations, and are less discomforting. These advantages are propelling the market's growth trajectory.

Continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring systems (CGMs) have revolutionized patient care, especially in ambulatory settings. Market players are intensifying collaborations and product developments to bolster their market foothold. For instance, in March 2023, BlueStar, a joint venture between Astellas Pharma and Welldoc, partnered with Roche DC Japan to integrate its blood glucose self-monitoring device, Accu-Check Guide Me, with BlueStar technology, which was slated for clinical trials in Japan in fiscal year 2023. With obesity rates on the rise, a surge in hereditary risks for type 2 diabetes, and a growing number of type 1 diabetes cases, the insulin pump segment is poised for further expansion.

The Prevalence of Diabetes is Rising

Diabetes poses a significant health challenge in Japan. The country's surging diabetes rates have set off alarm bells, prompting urgent responses from healthcare authorities and stakeholders.

Japan's Ministry of Health, Labor, and Welfare has highlighted diabetes as a top health priority. Of particular concern is the economic strain, especially for type 2 diabetes patients with additional conditions like hypertension, hyperlipidemia, or those facing complications.

Diabetes is on the rise across all age brackets in Japan, a surge attributed to a combination of factors: a burgeoning obese population, unhealthy dietary habits, and sedentary lifestyles. According to the International Diabetes Federation (IDF), Japan's diabetic populace is set to hit 10,542.7 thousand by 2030 and 10,117.9 thousand by 2045.

Japan's aging population, especially susceptible to diseases, combined with increasing obesity due to sedentary lifestyles and erratic eating patterns, are primary drivers behind the nation's climbing diabetes rates. As of December 2023, data from the Ministry of Internal Affairs and Communications (May 2024) revealed that nearly 30% of Japan's populace was aged 65 or older. With this aging demographic, Japan anticipates a further surge in diabetes cases, leading to increased demand for oral anti-diabetic medications.

Given the mounting prevalence of diabetes and Japan's proactive approach, the insulin infusion pump market is primed for substantial growth during the forecast period.

Japan's struggle with diabetes presents a dual narrative of challenges and opportunities. The nation's dedication to combatting this health crisis through innovative solutions and updated protocols will play a pivotal role in curbing the future health and economic ramifications of diabetes.

Japan Insulin Infusion Pump Industry Overview

Due to the existence of only a few big businesses operating internationally and locally, the insulin infusion pump market is concentrated. The competitive landscape includes an examination of a few well-known worldwide and local organizations, such as Medtronic PLC, Insulet Corporation, Ypsomed, Ascensia Diabetes Care, and Tandem Diabetes Care.

Japan Insulin Infusion Pump Market Leaders

Japan Insulin Infusion Pump Market News

• May 2024: Dexcom Japan LLC unveiled its latest offering, the real-time CGM Dexcom G7 CGM System in Japan. This system is available to all diabetes patients aged 2 years and above who self-administer insulin at least once daily and are covered under insurance medical care. This system is a complementary support for insulin pumps in the country,
• September 2023: Kobe University's findings highlighted the benefits of SAP therapy (insulin pump therapy with CGM function) for pregnant women with type 1 diabetes. The therapy was shown to mitigate the risk of fetal overgrowth.